A draft report from the Agency for Healthcare Research and Quality examines the research evidence relating to medication therapy management. (AHRQ Report) Medication therapy management, also sometimes referred to as pharmaceutical care, intensively focuses on the drug use of patients and identifies potential issues interfering with maximum value of drug therapies. It results in an individualized care plan for each patient and typically involves ongoing followup. CMS has required Medicare Advantage plans to engage a class of patients with high drug use or expenses in MTM and recently released a proposed rule which would greatly expand the patients for whom the MA plans should be doing MTM. The key questions addressed by the AHRQ report included describing the intervention components and implementation features, assess the effectiveness of MTM on outcomes, identify intervention features or patient characteristics that appear associated with effects on outcomes and identify any potential harms from MTM. Out of a large pool, only 36 studies met the criteria to be included in the review and most of those were considered low strength. Compared to usual care, the outcomes had low strength evidence of improving medication appropriateness, the use of generic medications and lowering the rate of hospitalization among heart failure patients. No benefit was found for most other outcomes examined, including general reduction of hospitalizations or quality of life, but again the evidence for no benefit is low strength. The authors called for a significant improvement in the research to evaluate MTM. The draft report should not be too discouraging to MTM vendors; like most AHRQ systematic reviews the problem is just a lack of good quality studies. The real-life experience of many plans deploying MTM is far more positive than the report would suggest. Properly done research will eventually catch up and validate MTM’s value.
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
Research
MedPAC 2019 Report to Congress
June 18, 2019
Headlines
Tags
Access
ACO
Care Management
Chronic Disease
Comparative Effectiveness
Consumer Directed Health
Consumers
Devices
Disease Management
Drugs
EHRs
Elder Care
End-of-Life Care
FDA
Financings
Genomics
Government
Health Care Costs
Health Care Quality
Health Care Reform
Health Insurance
Health Insurance Exchange
HIT
HomeCare
Hospital
Hospital Readmissions
Legislation
M&A
Malpractice
Meaningful Use
Medicaid
Medical Care
Medicare
Medicare Advantage
Mobile
Pay For Performance
Pharmaceutical
Physicians
Providers
Regulation
Repealing Reform
Telehealth
Telemedicine
Wellness and Prevention
Workplace
Related Posts
Commentary
April 19, 2024
Another Body Blow to Gender Dis-Affirmation
A review from Britain reveals the complete lack of any scientific evidence to support the…
Commentary
April 18, 2024
Progress Against Cancer
The US has made particularly good progress in treating cancer and limiting mortality, but much…
Commentary
April 17, 2024
I Am Done With Coronamonomania, Part 4, Vax Safety Edition
A somewhat lengthy examination of recent studies related mostly to vax safety, the results of…
I suspect that what from a distance appears to be a generic grouping of MTM providers, closer inspection will show a heterogeneity of approaches and efficacies. A quick Medi-span check for drug interactions might qualify as MTM and in which case I am not surprised that the (albeit low strength) evidence showed little benefit. An arrestingly high proportions of hospital readmissions seem to be as a result of ‘medication issues’ so I believe that a detailed MTM review might potentially be a key tool in this regard.